Skip to main content

ORIGINAL RESEARCH article

Front. Parasitol.

Sec. Antiparasitic Drugs and Drug Resistance

Volume 4 - 2025 | doi: 10.3389/fpara.2025.1512012

This article is part of the Research Topic Biomolecular Approaches to Trichomoniasis: Epidemiology, Diagnosis, and Treatment View all articles

Trichocystatin-2 from Trichomonas vaginalis: Role of N-terminal cysteines in aggregation, protease inhibition, and trichomonal cysteine protease-dependent cytotoxicity on HeLa cells

Provisionally accepted
Verónica Aranda-Chan Verónica Aranda-Chan 1Montserrat Gutiérrez-Soto Montserrat Gutiérrez-Soto 1Claudia Ivonne Flores-Pucheta Flores-Pucheta Claudia Ivonne Flores-Pucheta Flores-Pucheta 1Octavio Montes-Flores Octavio Montes-Flores 1Rossana Arroyo Rossana Arroyo 2Jaime Ortega-Lopez Jaime Ortega-Lopez 1*
  • 1 Departmento de Biotecnología y Bioingeniería, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Mexico City, Mexico
  • 2 Departamento de Infectómica y Patogénesis Molecular. Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Mexico City, Mexico

The final, formatted version of the article will be published soon.

    Trichomonas vaginalis is a protozoan parasite that causes trichomoniasis, the most common nonviral neglected sexually transmitted disease worldwide. Biomarkers and therapeutic targets, including specific trichomonad cysteine proteases (CPs) and their endogenous inhibitors, have been identified to diagnose and treat this disease. Trichocystatin 2 (TC-2) was previously identified as one of the three endogenous inhibitors of the parasite’s cathepsin L-like CPs, including TvCP39, which is involved in T. vaginalis cytotoxicity and is a potential therapeutic target. TC-2 contains five cysteines, including four located in the N-terminal sequence. These cysteines may be responsible for the formation of multimers of the recombinant protein expressed in E. coli. To determine whether these cysteines are responsible for the formation of TC-2 multimers and the effect of the N-terminus on CP inhibition, a recombinant TC-2 mutant was expressed, purified, and characterized. In silico and experimental analyses revealed that wild-type and mutant TC-2 proteins presented similar results in terms of secondary and tertiary structure prediction and high thermal stability. However, compared with that of wild-type TC-2, multimer formation was significantly reduced in the mutant lacking the four N-terminal cysteines, leading to a significant reduction in papain inhibition but not in trichomonal CP activity. These results support the hypothesis that the four cysteines located in the N-terminal region are responsible for aggregation, and their deletion affected the interaction of TC-2 with papain without affecting its inhibitory activity on homologous target proteases that are crucial for T. vaginalis virulence. Our results provide essential data supporting the use of TC-2 as a potential therapeutic target

    Keywords: Trichocystin-2, Trichomonas vaginalis, protein aggregation, Cysteine protease inhibitors, Cytotoxicity Trichocystin-2

    Received: 16 Oct 2024; Accepted: 27 Feb 2025.

    Copyright: © 2025 Aranda-Chan, Gutiérrez-Soto, Flores-Pucheta, Montes-Flores, Arroyo and Ortega-Lopez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jaime Ortega-Lopez, Departmento de Biotecnología y Bioingeniería, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Mexico City, Mexico

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more